<DOC>
	<DOCNO>NCT01050491</DOCNO>
	<brief_summary>Introduction . Despite adequate steroid therapy , subpopulation approximately 10 % asthmatic develop severe persistent airflow obstruction . It widely agree latter consequence remodel process airway , characterized increase airway smooth muscle mass , mucus gland hypertrophy , increase thickness subepithelial basement membrane , extracellular matrix protein deposition , angiogenesis , fibroblast myofibroblast accumulation . These phenomenon responsible airway wall thickening decrease airway caliber lead persistent airflow obstruction . Endothelin-1 ( ET-1 ) small peptide , synthesize lung airway epithelial smooth muscle cell , well inflammatory cell . ET-1 induces bronchoconstriction , mediate eosinophils recruitment allergic inflammation contribute airway remodel induce fibroblast smooth muscle cell differentiation proliferation . In recent work Inserm Unit 700 , show ET-1 overexpressed epithelial cell severe asthmatic patient compare patient less severe disease , ET-1 expression strongly correlate airway obstruction ( measure FEV1 ) bronchial biopsy airway smooth muscle area . In another study , show polymorphism receptor ET-1 strongly associate degree airway obstruction population asthmatic patient . All data suggest inhibition ET-1 pathway could potential therapeutic option patient steroids refractory asthma irreversible airway obstruction . Bosentan , specific inhibitor ET-1 receptor actually use patient pulmonary hypertension , improve survival inhibits vascular remodel . Aim strategy . To study impact airway remodel clinical status antagonist endothelin receptor ( Sitaxentan 100mg/day ) 12-month period , prospective randomise placebo-controlled trial involve two parallel group 25 severe asthmatic patient irreversible airflow obstruction ( FEV1≤ 70 % predict ) . Various hallmark airway remodel analyze bronchial biopsy specimen immunohistochemistry morphometry . These finding correlate result pulmonary function test . Twenty-five patient include group . Remodeling measure bronchial biopsy perform fiberoptic bronchoscopy inclusion one year , assess smooth muscle area , submucosal fibroblast count basement membrane thickness . Every 3 month , bronchial obstruction ( FEV1 ) , clinical status , asthma exacerbation , steroid use , need emergency care , asthma symptom quality life assess . Evaluation airway inflammation assess every 3 month exhale NO induce sputum cytology . This proof concept study validate ET-1 new molecular target treat airway remodel patient severe asthma .</brief_summary>
	<brief_title>Study Effects Sitaxsentan Airway Remodeling Patients With Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Airway Remodeling</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>50 non smoking ( 25 active treatment 25 placebo ) patient severe asthmatic patient ( age 18 less 70 ) irreversible airflow obstruction ( FEV1≤ 70 % predict ) Abnormal liver chemistry inclusion , female without acceptable contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>asthma</keyword>
	<keyword>airway remodel</keyword>
	<keyword>airway obstruction</keyword>
</DOC>